Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.50 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662490 | 0.86 | DPP4 (0.49) | DPP4DPP7DPP8 | |
| SCHEMBL6444430 | 0.84 | DPP4 (0.67) | DPP4DPP7DPP8 | |
| SCHEMBL6444425 | 0.82 | DPP4 (0.40) | DPP4NR1D1 | |
| SCHEMBL8282472 | 0.81 | DPP4 (0.55) | DPP4NR1D1DPP7DPP8 | |
| SCHEMBL8281247 | 0.79 | DPP4 (0.52) | DPP4DPP7DPP8 | |
| SCHEMBL8282334 | 0.76 | DPP4 (0.54) | DPP4DPP7DPP8 | |
| SCHEMBL21067940 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP8 | |
| SCHEMBL21067942 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP8 | |
| SCHEMBL8293182 | 0.76 | DPP4 (0.55) | DPP4DPP7DPP8 | |
| SCHEMBL5661437 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265301-A1 | Dpp-IV Inhibitors | DPP4, DPP8, DPP7 | DPP4 1/4885NR1D1 1769/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.